Medical School · Year 3 · Neurology · includes a quiz and discussion video

Seminar 08: Dementia and Cognitive Disorders

Year 3: Neurology Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Define dementia and differentiate from normal aging
2. Recognize major dementia syndromes
3. Evaluate patients with cognitive complaints
4. Diagnose Alzheimer's disease and other dementias
5. Identify reversible causes of cognitive impairment
6. Apply pharmacological and non-pharmacological management strategies

Seminar Outline

I. Overview of Dementia

Dementia represents an acquired decline in cognitive function affecting multiple domains that is sufficiently severe to interfere with daily functioning and independence. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, uses the term major neurocognitive disorder to describe this condition, distinguishing it from mild neurocognitive disorder (analogous to mild cognitive impairment) in which cognitive decline is present but daily function remains intact. Delirium, an acute confusional state characterized by fluctuating attention and awareness, must be distinguished from dementia, though the two conditions may coexist and delirium may unmask underlying cognitive impairment. The distinction between these entities has important diagnostic and management implications.

The epidemiology of dementia reflects its strong association with advancing age. Prevalence increases from approximately one to two percent among adults aged sixty-five to seventy to over thirty percent among those over eighty-five years. Alzheimer's disease accounts for sixty to eighty percent of dementia cases, making it the most common etiology. Vascular contributions to cognitive impairment represent the second most common cause, though mixed pathology combining Alzheimer's disease and vascular disease is increasingly recognized as the norm rather than the exception. The economic impact of dementia is substantial, with costs including medical care, long-term services, and informal caregiving reaching hundreds of billions of dollars annually.

Distinguishing normal aging from pathological cognitive decline requires understanding the cognitive changes expected with healthy aging. Normal aging involves occasional word-finding difficulty, slowed processing speed, and minor memory inefficiencies such as briefly forgetting where one placed keys, but orientation, judgment, and the ability to perform daily activities remain intact. Dementia produces more severe memory impairment affecting the ability to recall recent conversations and events, disorientation to time or place, impaired judgment affecting decision-making, and progressive decline in the ability to manage instrumental activities such as finances, medications, and driving. The trajectory of symptoms also differs, with normal aging showing stability while dementia demonstrates progressive deterioration.

The cognitive domains assessed in dementia evaluation encompass memory, language, executive function, visuospatial abilities, attention, and social cognition. Memory includes learning new information, recall, and recognition. Language encompasses naming, fluency, and comprehension. Executive function involves planning, judgment, problem-solving, and cognitive flexibility. Visuospatial abilities include navigation, spatial orientation, and constructional abilities. Attention comprises concentration, divided attention, and working memory. Social cognition includes emotion recognition, empathy, and appropriate social behavior. Different dementia syndromes affect these domains in characteristic patterns that aid differential diagnosis.

<image>Panel A: Prevalence of dementia by age group showing exponential increase with advancing age and relative proportions of different etiologies. Panel B: Normal aging versus dementia comparison showing cognitive domains, functional abilities, and trajectory differences. Panel C: Cognitive domains wheel showing memory, language, executive, visuospatial, attention, and social cognition with assessment methods. Panel D: DSM-5 criteria for major and mild neurocognitive disorders with distinguishing features.</image>

II. Approach to Cognitive Complaints

The clinical evaluation of cognitive complaints begins with comprehensive history taking from both the patient and an informant, typically a family member or close friend who can provide objective observations about cognitive and functional changes. Informant history often proves more accurate than patient report, particularly in dementias affecting insight. Key questions address the nature and timeline of symptoms, whether onset was gradual or sudden, and whether progression has been stepwise or continuous. Memory difficulties, language problems, getting lost in familiar places, personality or behavioral changes, and concerns about safety including leaving the stove on or wandering provide specific information guiding diagnosis.

Functional assessment determines whether cognitive changes have crossed the threshold into dementia by affecting daily life. Basic activities of daily living include bathing, dressing, toileting, transferring, continence, and feeding, reflecting the most fundamental self-care abilities. Instrumental activities of daily living represent higher-order functions including managing medications, handling finances, shopping, preparing meals, using transportation, and managing household responsibilities. Decline in instrumental activities typically precedes loss of basic activities as dementia progresses. Safety assessment addresses driving ability, medication management, fire safety, and risk of financial exploitation, informing both diagnosis and care planning.

Bedside cognitive screening instruments provide standardized assessment of multiple cognitive domains. The Mini-Mental State Examination, scored out of thirty points, assesses orientation, registration, attention, recall, language, and visuospatial construction, with scores below twenty-four generally suggesting cognitive impairment. The Montreal Cognitive Assessment offers greater sensitivity for detecting mild cognitive impairment, particularly in executive dysfunction, with scores below twenty-six suggesting impairment. The Mini-Cog combines a three-word recall with clock drawing and can be completed in approximately three minutes. For comprehensive assessment, referral for formal neuropsychological testing provides detailed characterization of cognitive domains and comparison to normative data.

The Montreal Cognitive Assessment systematically evaluates multiple cognitive domains within its thirty-point structure. Visuospatial and executive functions are assessed through trail-making, cube copying, and clock drawing tasks. Naming is tested with animal pictures. Memory involves learning and delayed recall of five words. Attention is evaluated through digit span, serial subtraction, and target detection tasks. Language includes sentence repetition and verbal fluency. Abstraction assesses conceptual thinking through similarity judgments. Orientation to time and place completes the assessment. Education-adjusted scoring adds one point for individuals with twelve years of education or less. The pattern of deficits across domains helps distinguish different dementia etiologies.

<image>Panel A: History-taking checklist showing patient and informant questions addressing memory, language, behavior, and safety concerns. Panel B: Functional assessment hierarchy showing instrumental and basic activities of daily living in order of typical decline. Panel C: Cognitive screening comparison showing MMSE, MoCA, and Mini-Cog content, administration time, and sensitivity characteristics. Panel D: MoCA score interpretation with domain-specific deficit patterns suggesting different dementia etiologies.</image>

III. Diagnostic Evaluation

Laboratory testing in the evaluation of cognitive impairment serves to identify potentially reversible causes and contributing factors. Standard screening includes complete blood count to assess for anemia or infection, comprehensive metabolic panel to evaluate electrolytes and renal and hepatic function, thyroid-stimulating hormone to exclude hypothyroidism, and vitamin B12 level to identify deficiency. Syphilis serology and HIV testing should be considered based on risk factors. Sedimentation rate or C-reactive protein may help identify inflammatory conditions. While these reversible causes account for a small minority of dementia cases, their identification allows treatment that may improve or stabilize cognition.

Neuroimaging plays a central role in dementia evaluation by identifying structural abnormalities, characteristic atrophy patterns, and vascular disease. Magnetic resonance imaging provides superior soft tissue contrast and is preferred over computed tomography when available and not contraindicated. In Alzheimer's disease, MRI demonstrates hippocampal and medial temporal lobe atrophy, often with subsequent parietal and generalized cortical atrophy. Frontotemporal dementia shows frontal and anterior temporal atrophy, while vascular dementia demonstrates white matter hyperintensities, lacunar infarcts, and evidence of prior strokes. Mass lesions, subdural hematomas, and hydrocephalus can be identified and may represent treatable causes of cognitive impairment.

Biomarkers have transformed the diagnosis of Alzheimer's disease from a clinical-pathological construct to a biologically defined entity. Cerebrospinal fluid analysis demonstrates reduced amyloid-beta 42 reflecting deposition in plaques, elevated total tau reflecting neuronal injury, and elevated phosphorylated tau reflecting tangle formation in Alzheimer's disease. Amyloid positron emission tomography using tracers such as florbetapir, florbetaben, or flutemetamol detects fibrillar amyloid deposition in the brain. Tau PET imaging, while emerging from research settings, allows visualization of tangle pathology. Fluorodeoxyglucose PET demonstrates patterns of hypometabolism that differ among dementia syndromes, with temporoparietal hypometabolism characteristic of Alzheimer's disease. Blood-based biomarkers including plasma amyloid and phosphorylated tau are increasingly available for clinical use.

The evaluation must systematically consider potentially reversible causes of cognitive impairment even though they account for a small proportion of cases. Depression can produce cognitive complaints termed pseudodementia that may improve substantially with treatment. Vitamin B12 deficiency causes cognitive impairment potentially reversible with supplementation, particularly if identified early. Hypothyroidism contributes to cognitive slowing that may improve with thyroid hormone replacement. Normal pressure hydrocephalus presents with the triad of gait disturbance, cognitive impairment, and urinary incontinence, with potential improvement following shunting. Medications, particularly those with anticholinergic properties and sedatives, commonly contribute to cognitive impairment in older adults. Subdural hematoma following head trauma, even minor, should be considered in patients with recent cognitive decline.

<image>Panel A: Laboratory evaluation algorithm showing standard screening tests and additional testing based on clinical suspicion. Panel B: MRI atrophy patterns comparison showing hippocampal atrophy in Alzheimer's disease, frontotemporal atrophy in FTD, and vascular changes in vascular dementia. Panel C: Biomarker interpretation showing CSF amyloid and tau patterns, amyloid PET, and FDG-PET hypometabolism patterns. Panel D: Reversible causes of cognitive impairment checklist with screening approach for each.</image>

IV. Alzheimer's Disease

Alzheimer's disease represents the most common cause of dementia, affecting millions of individuals worldwide with increasing prevalence as the population ages. Risk factors include advancing age, which represents the strongest risk factor with prevalence doubling approximately every five years after age sixty-five. Family history confers increased risk, particularly with affected first-degree relatives. The apolipoprotein E epsilon-4 allele represents the most significant genetic risk factor, increasing risk two to three-fold with one copy and up to twelve-fold with two copies. Rare autosomal dominant forms caused by mutations in APP, PSEN1, or PSEN2 genes account for less than one percent of cases and typically present before age sixty-five. Female sex confers approximately two-fold increased risk, even accounting for longer life expectancy.

The clinical presentation of Alzheimer's disease classically begins with impairment in episodic memory, particularly the ability to learn and retain new information. Patients repeatedly ask the same questions, forget recent conversations and events, and misplace objects. Language difficulties emerge, initially as word-finding difficulty progressing to anomia and eventually impoverished speech. Visuospatial dysfunction manifests as getting lost in familiar environments, difficulty parking, and inability to copy figures or drawings. Executive dysfunction affects planning, judgment, and problem-solving. Behavioral symptoms including apathy, depression, and later agitation and psychosis commonly develop. The course is gradually progressive over years, with patients eventually losing the ability to perform basic self-care.

The pathophysiology of Alzheimer's disease involves two hallmark protein aggregates. Extracellular amyloid plaques consist of aggregated amyloid-beta peptide, derived from processing of the amyloid precursor protein, depositing in the brain parenchyma. Intracellular neurofibrillary tangles contain hyperphosphorylated tau protein that aggregates into paired helical filaments. The relationship between amyloid and tau pathology remains an area of active investigation, with the amyloid cascade hypothesis proposing that amyloid accumulation initiates downstream tau pathology and neurodegeneration. Synaptic loss and neuronal death produce progressive atrophy, beginning in the hippocampus and entorhinal cortex and spreading to involve association cortices. Cholinergic neuron loss in the nucleus basalis of Meynert provides the rationale for cholinesterase inhibitor therapy.

The diagnosis of Alzheimer's disease integrates clinical assessment with biomarker information. Clinical criteria require progressive cognitive decline affecting memory plus at least one other domain, with impairment in daily function, and exclusion of other causes. Biomarker support, while not required for clinical diagnosis, provides greater diagnostic certainty and is essential for clinical trial enrollment and increasingly for treatment decisions. The National Institute on Aging and Alzheimer's Association framework defines Alzheimer's disease biologically by the presence of amyloid (A), tau (T), and neurodegeneration (N), with combinations of these markers providing staging information. MRI demonstrating medial temporal atrophy supports the diagnosis but is not specific.

<image>Panel A: Alzheimer's disease risk factors diagram showing age, genetics (APOE epsilon-4, autosomal dominant genes), family history, and female sex with relative risk magnitudes. Panel B: Clinical progression timeline showing memory impairment, language decline, visuospatial dysfunction, and behavioral symptoms over disease course. Panel C: Pathophysiology illustration showing amyloid plaque formation, tau tangle accumulation, and neuronal loss with hippocampal atrophy. Panel D: Diagnostic framework showing clinical criteria, biomarker categories (A/T/N), and staging approach.</image>

V. Vascular Cognitive Impairment

Vascular cognitive impairment encompasses a spectrum of cognitive syndromes resulting from cerebrovascular disease, ranging from mild vascular cognitive impairment to vascular dementia and including mixed dementia combining vascular and neurodegenerative pathology. The latter may represent the most common form of dementia in older adults, as vascular pathology and Alzheimer's disease frequently coexist. The relationship between vascular and neurodegenerative pathology is likely bidirectional, with vascular disease lowering the threshold for clinical expression of neurodegenerative pathology and potentially accelerating its progression.

Clinical features of vascular cognitive impairment differ from the amnestic presentation typical of Alzheimer's disease. Executive dysfunction, including impaired planning, organization, mental flexibility, and processing speed, is often more prominent than memory impairment. Motor findings including gait disturbance, focal weakness, and pseudobulbar affect may be present. The course may be stepwise with sudden deteriorations corresponding to new vascular events, or more gradual in the setting of progressive small vessel disease. Mood disturbance, apathy, and depression occur commonly. A history of stroke, transient ischemic attack, or vascular risk factors including hypertension, diabetes, hyperlipidemia, and atrial fibrillation supports vascular contributions to cognitive impairment.

Several subtypes of vascular cognitive impairment are recognized based on the distribution and mechanism of vascular pathology. Multi-infarct dementia results from the accumulated burden of multiple cortical strokes. Strategic infarct dementia occurs when a single stroke affects a cognitively critical region such as the thalamus, angular gyrus, or basal forebrain. Small vessel disease produces diffuse white matter changes visible as hyperintensities on MRI, along with lacunar infarcts in subcortical structures. Subcortical ischemic vascular dementia represents the most common vascular dementia subtype, manifesting as executive dysfunction, processing speed slowing, and gait disturbance with relatively preserved episodic memory.

Management of vascular cognitive impairment emphasizes prevention through aggressive management of vascular risk factors. Blood pressure control reduces the risk of subsequent strokes and may slow cognitive decline. Antiplatelet therapy or anticoagulation as indicated for stroke prevention, statin therapy for hyperlipidemia, glycemic control for diabetes, and smoking cessation all contribute to risk reduction. Cholinesterase inhibitors have shown modest benefit in vascular dementia, particularly mixed dementia, and may be considered. Cognitive rehabilitation following stroke may improve specific deficits. Addressing depression and providing caregiver support are important components of comprehensive management.

<image>Panel A: Vascular cognitive impairment spectrum showing mild VCI, vascular dementia, and mixed dementia with relative prevalence. Panel B: Clinical features comparison showing executive dysfunction predominance, stepwise course, motor findings, and vascular risk factor history. Panel C: Vascular dementia subtypes diagram showing multi-infarct, strategic infarct, and small vessel disease patterns with representative imaging. Panel D: Management approach showing vascular risk factor control, pharmacotherapy options, and comprehensive care components.</image>

VI. Frontotemporal Dementia

Frontotemporal dementia encompasses a group of neurodegenerative disorders characterized by progressive changes in behavior, personality, language, or executive function, typically with relative preservation of memory in early stages. The age of onset is earlier than typical Alzheimer's disease, with most patients presenting between ages forty-five and sixty-five, making it a leading cause of dementia in the presenile age group. A substantial genetic component exists, with thirty to fifty percent of patients having a family history of dementia or related neurodegenerative disease. Mutations in genes including MAPT (encoding tau), GRN (encoding progranulin), and the C9orf72 hexanucleotide repeat expansion account for a significant proportion of familial cases.

The behavioral variant of frontotemporal dementia represents the most common subtype, characterized by early and progressive changes in personality, social conduct, and behavior. Disinhibition manifests as socially inappropriate behavior, loss of manners, and impulsive actions. Apathy and loss of sympathy or empathy produce withdrawal from previously valued relationships and activities. Compulsive and stereotyped behaviors including ritualistic behaviors, hoarding, and repetitive movements develop. Hyperorality with dietary changes, often involving preference for sweets or overconsumption, is characteristic. Executive function is impaired, while memory remains relatively preserved in early stages, distinguishing behavioral variant frontotemporal dementia from Alzheimer's disease. Neuroimaging demonstrates frontal and anterior temporal atrophy.

The primary progressive aphasias are language-predominant variants of frontotemporal lobar degeneration. Semantic variant primary progressive aphasia produces progressive loss of word comprehension and object knowledge, with fluent but increasingly empty speech characterized by circumlocution and substitution of generic terms for specific words. Nonfluent agrammatic variant presents with effortful, halting speech, grammatical errors, and apraxia of speech, with relatively preserved word comprehension. Logopenic variant, which is often associated with underlying Alzheimer's disease pathology, features word-finding difficulty with preserved grammar and single-word comprehension. Each variant has characteristic patterns of atrophy on neuroimaging, with semantic variant showing anterior temporal atrophy, nonfluent variant showing left posterior frontal and insular atrophy, and logopenic variant showing left posterior temporal and parietal atrophy.

Frontotemporal dementia has associations with other neurodegenerative conditions. FTD with motor neuron disease features the behavioral or language changes of FTD accompanied by clinical evidence of amyotrophic lateral sclerosis, carrying a particularly poor prognosis. Progressive supranuclear palsy and corticobasal syndrome share clinical and pathological overlap with FTD-spectrum disorders. No disease-modifying treatments are available for frontotemporal dementia. Management focuses on behavioral interventions, environmental modifications, caregiver education and support, and judicious use of pharmacotherapy for specific symptoms. Selective serotonin reuptake inhibitors may help compulsive behaviors, and low-dose antipsychotics may be necessary for severe agitation, though all medications should be used cautiously given the potential for adverse effects.

<image>Panel A: Frontotemporal dementia epidemiology showing earlier age of onset, genetic contribution, and comparison with Alzheimer's disease. Panel B: Behavioral variant FTD features illustrating disinhibition, apathy, compulsive behaviors, hyperorality, and executive dysfunction with relative memory preservation. Panel C: Primary progressive aphasia variants comparison showing semantic, nonfluent agrammatic, and logopenic presentations with characteristic atrophy patterns. Panel D: FTD-associated syndromes diagram showing overlap with motor neuron disease, PSP, and corticobasal syndrome.</image>

VII. Lewy Body Dementia

Lewy body dementia encompasses two closely related conditions: dementia with Lewy bodies and Parkinson's disease dementia. Both are characterized pathologically by alpha-synuclein aggregates forming Lewy bodies in cortical and subcortical neurons. The distinction between dementia with Lewy bodies and Parkinson's disease dementia is largely temporal: dementia occurring before or within one year of parkinsonism onset is classified as dementia with Lewy bodies, while dementia developing more than one year after established Parkinson's disease is classified as Parkinson's disease dementia. The underlying pathology and clinical management are similar for both conditions.

The clinical features of dementia with Lewy bodies are distinctive and aid in differentiation from Alzheimer's disease. Fluctuating cognition manifests as marked variations in attention and alertness, with patients having periods of near-normal function alternating with episodes of confusion and drowsiness. Visual hallucinations are typically well-formed and detailed, often depicting people or animals, and may occur early in the disease course before significant cognitive decline. Parkinsonism, including rigidity, bradykinesia, and gait disturbance, may be present, though rest tremor is less common than in idiopathic Parkinson's disease. REM sleep behavior disorder, characterized by dream enactment behaviors during REM sleep due to loss of normal muscle atonia, often precedes cognitive decline by years and represents a prodromal manifestation of alpha-synucleinopathy.

Diagnostic criteria for probable dementia with Lewy bodies require dementia plus two or more core features or one core feature plus one or more indicative biomarkers. The core clinical features are fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and spontaneous parkinsonism. Indicative biomarkers include reduced dopamine transporter uptake in basal ganglia on SPECT or PET imaging, abnormal iodine-123 MIBG myocardial scintigraphy indicating cardiac sympathetic denervation, and polysomnographic confirmation of REM sleep without atonia. Supportive features include severe sensitivity to antipsychotic medications, postural instability, falls, autonomic dysfunction, depression, and apathy.

Management of dementia with Lewy bodies requires careful attention to medication selection given the severe sensitivity to antipsychotic medications that can cause life-threatening neuroleptic sensitivity reactions. Traditional antipsychotics are contraindicated, and even atypical antipsychotics should be used only when absolutely necessary and with extreme caution, preferring quetiapine or pimavanserin over others. Cholinesterase inhibitors, particularly rivastigmine, have demonstrated efficacy for cognitive and neuropsychiatric symptoms and are considered first-line treatment. Carbidopa-levodopa may be used for parkinsonism but may exacerbate hallucinations and confusion. REM sleep behavior disorder is treated with melatonin or low-dose clonazepam. Comprehensive management addresses falls, orthostatic hypotension, constipation, and other features of the condition.

<image>Panel A: Dementia with Lewy bodies versus Parkinson's disease dementia timeline showing temporal relationship between cognitive and motor symptom onset. Panel B: Core clinical features illustration showing fluctuating cognition, visual hallucinations, parkinsonism, and REM sleep behavior disorder. Panel C: Diagnostic framework showing core features, indicative biomarkers, and supportive features contributing to diagnostic probability. Panel D: Management algorithm emphasizing antipsychotic sensitivity warning, cholinesterase inhibitor use, and approach to parkinsonism and RBD treatment.</image>

VIII. Other Dementias

Normal pressure hydrocephalus presents with the classic triad of gait disturbance, dementia, and urinary incontinence. The gait abnormality typically appears first and is characterized as a magnetic, shuffling, wide-based gait with difficulty initiating steps, often described as appearing that the feet are stuck to the floor. The cognitive impairment follows a subcortical pattern with prominent psychomotor slowing, attention deficits, and apathy, rather than the cortical pattern of Alzheimer's disease. Urinary symptoms begin as urgency and frequency, progressing to incontinence. Neuroimaging demonstrates ventriculomegaly disproportionate to the degree of cortical atrophy, with Evans index greater than 0.3. Diagnosis is supported by improvement following large-volume lumbar puncture removing thirty to fifty milliliters of cerebrospinal fluid, assessed through gait evaluation before and after the procedure. Treatment involves ventriculoperitoneal shunt placement, with gait most likely to improve and cognitive improvement variable.

Prion diseases are rapidly progressive dementias caused by misfolded prion protein. Sporadic Creutzfeldt-Jakob disease is the most common form, presenting with rapidly progressive dementia evolving over weeks to months, accompanied by myoclonus, ataxia, visual disturbances, and pyramidal or extrapyramidal signs. The characteristic MRI finding is restricted diffusion (hyperintensity on diffusion-weighted imaging) in the cortex and basal ganglia. Electroencephalography may demonstrate periodic sharp wave complexes. Cerebrospinal fluid testing for 14-3-3 protein has limited sensitivity and specificity, while real-time quaking-induced conversion assay for prion protein provides high sensitivity and specificity. The disease is invariably fatal, typically within months of symptom onset, and treatment is supportive. Variant Creutzfeldt-Jakob disease, associated with bovine spongiform encephalopathy, presents with psychiatric symptoms in younger individuals.

Alcohol-related cognitive impairment encompasses several syndromes. Wernicke encephalopathy is an acute syndrome caused by thiamine deficiency, presenting with the classic triad of encephalopathy, oculomotor abnormalities, and gait ataxia, though the complete triad is present in a minority of cases. Treatment with intravenous thiamine is urgent, with glucose administration potentially precipitating or worsening Wernicke encephalopathy if thiamine is not given first. Korsakoff syndrome represents the chronic amnestic state following Wernicke encephalopathy, characterized by profound anterograde amnesia with confabulation and relative preservation of other cognitive domains. Prevention through thiamine supplementation in at-risk individuals is far more effective than treatment of established Korsakoff syndrome.

Autoimmune and inflammatory causes of cognitive impairment require consideration, particularly in subacute presentations. Autoimmune encephalitis, including anti-NMDA receptor encephalitis, presents with subacute onset of cognitive impairment, psychiatric symptoms, seizures, and movement disorders. Hashimoto encephalopathy occurs in association with elevated thyroid antibodies, though the pathogenic mechanism is uncertain. Central nervous system vasculitis causes cognitive impairment through multiple mechanisms including stroke and diffuse inflammatory injury. These conditions are important to recognize because immunomodulatory treatment may produce improvement or stabilization that would not occur with neurodegenerative conditions.

<image>Panel A: Normal pressure hydrocephalus triad showing magnetic gait, subcortical dementia, and urinary incontinence with characteristic imaging and lumbar puncture tap test response. Panel B: Creutzfeldt-Jakob disease features showing rapid progression, myoclonus, and characteristic MRI (cortical ribboning) and EEG (periodic sharp waves) findings. Panel C: Wernicke-Korsakoff syndrome pathway from thiamine deficiency through acute Wernicke encephalopathy to chronic Korsakoff syndrome with prevention and treatment points. Panel D: Autoimmune encephalitis recognition features and antibody-associated syndromes with treatment approach.</image>

IX. Management of Dementia

Pharmacological management of Alzheimer's disease includes cholinesterase inhibitors and the NMDA receptor antagonist memantine. Donepezil, rivastigmine, and galantamine inhibit acetylcholinesterase, increasing synaptic acetylcholine availability to compensate for loss of cholinergic neurons. These medications provide modest symptomatic improvement in cognition and function, equivalent to delaying decline by approximately six to twelve months, and are approved for mild to severe Alzheimer's disease. Common side effects relate to cholinergic excess and include nausea, diarrhea, decreased appetite, and bradycardia. Rivastigmine is also approved for Parkinson's disease dementia. Memantine, an NMDA receptor antagonist, is approved for moderate to severe Alzheimer's disease and may be used in combination with cholinesterase inhibitors.

Disease-modifying therapies targeting amyloid pathology represent a new therapeutic frontier in Alzheimer's disease. Lecanemab, an anti-amyloid monoclonal antibody that preferentially binds soluble amyloid protofibrils, demonstrated modest slowing of cognitive and functional decline in patients with early Alzheimer's disease confirmed by amyloid biomarkers. Donanemab, targeting deposited amyloid plaque, has shown similar results. These therapies require confirmation of amyloid positivity before treatment and monitoring with serial MRI for amyloid-related imaging abnormalities including edema and microhemorrhages, which occur in a significant proportion of patients. Patient selection, balancing potential benefits against risks and treatment burden, requires careful discussion with patients and families.

Non-pharmacological interventions form the foundation of comprehensive dementia care. Cognitive stimulation through activities, socialization, and engagement may help maintain function. Physical exercise has demonstrated benefits for cognition and may slow decline. Music therapy can reduce behavioral symptoms and improve quality of life. Caregiver education regarding the nature of the disease, communication strategies, and behavioral management is essential. Environmental modifications including simplification, safety measures, and visual cues can support function and reduce confusion. Structured routines provide predictability that can reduce anxiety and behavioral symptoms. Planning for future care needs, including legal and financial planning, should occur early while the patient retains capacity to participate in decisions.

Comprehensive dementia care addresses multiple domains beyond cognition. Driving assessment should occur early, as dementia eventually impairs the judgment and reaction time necessary for safe driving. Nutritional support addresses the weight loss that commonly occurs as dementia progresses. Fall prevention is important given the increased fall risk, particularly in conditions with motor involvement. Pain management requires attention as patients may have difficulty communicating discomfort, which may manifest as behavioral changes. Advance care planning, including discussion of goals of care and documentation of preferences through advance directives, should occur while the patient can participate. Support services including adult day programs, home health, and eventually long-term care placement should be discussed with families.

<image>Panel A: Cholinesterase inhibitor comparison showing donepezil, rivastigmine, and galantamine dosing, formulations, and side effect profiles. Panel B: Disease-modifying therapy requirements showing amyloid confirmation, ARIA monitoring protocol, and patient selection considerations. Panel C: Non-pharmacological intervention pyramid showing cognitive stimulation, exercise, caregiver support, environmental modifications, and activity engagement. Panel D: Comprehensive dementia care checklist addressing driving, nutrition, falls, pain, advance planning, and support services.</image>

X. Behavioral and Psychological Symptoms

Behavioral and psychological symptoms of dementia affect the majority of patients at some point during the disease course and represent major sources of caregiver distress and predictors of institutionalization. These symptoms include mood disturbances such as depression, anxiety, and apathy; psychotic symptoms including hallucinations and delusions; agitation and aggression; and other behavioral changes including wandering, sleep disturbances, and repetitive behaviors. The approach to these symptoms begins with systematic assessment to identify potential triggers or contributing factors before considering pharmacological intervention.

Non-pharmacological approaches represent first-line management for behavioral symptoms. Identifying and addressing triggers is fundamental, as behavioral changes may reflect unmet needs such as pain, infection, constipation, hunger, or environmental factors. Urinary tract infections, in particular, commonly precipitate behavioral changes in patients with dementia. Environmental modifications including reducing stimulation, improving lighting, and maintaining consistent routines can reduce confusion and agitation. Redirection and distraction techniques allow caregivers to defuse potentially difficult situations. Caregiver training in communication techniques, validation approaches, and behavioral management reduces caregiver stress while improving patient outcomes. Music therapy, pet therapy, and activities tailored to the patient's interests and abilities can reduce agitation and improve quality of life.

Pharmacological treatment of behavioral symptoms is reserved for situations where non-pharmacological approaches are insufficient and symptoms pose risk to the patient or others or cause significant distress. Depression in dementia responds to selective serotonin reuptake inhibitors including sertraline and citalopram. Agitation may respond to these agents as well, with citalopram having some evidence for reducing agitation though concerns about QTc prolongation limit dosing. Sleep disturbance may benefit from trazodone or melatonin rather than benzodiazepines, which increase fall and confusion risk. Antipsychotic medications carry significant risks including increased mortality in patients with dementia and should be used only when symptoms are severe and pose clear risk, with the lowest effective dose for the shortest necessary duration.

Caregiver support is an essential component of dementia management, as caregiver burden and burnout adversely affect both caregiver health and patient care. Education about the disease, its expected course, and management strategies helps caregivers understand and cope with challenging behaviors. Respite care through adult day programs, in-home care, or short-term residential stays allows caregivers time for self-care. Support groups, including those offered through the Alzheimer's Association, provide emotional support and practical advice from others facing similar challenges. Monitoring for caregiver depression and providing appropriate referrals is important. Planning for increasing care needs, including discussion of long-term care options, should occur proactively rather than in crisis. The entire family system requires support, and family meetings may help align expectations and distribute caregiving responsibilities.

<image>Panel A: Behavioral and psychological symptoms categories showing mood, psychotic, agitation, and other behavioral symptoms with prevalence estimates. Panel B: Non-pharmacological management hierarchy showing trigger identification, environmental modification, redirection techniques, and caregiver training as foundation. Panel C: Pharmacological approach diagram showing SSRIs for depression and agitation, trazodone for sleep, and antipsychotic risks and indications. Panel D: Caregiver support framework addressing education, respite, support groups, burnout monitoring, and long-term planning.</image>

Summary

• Dementia requires acquired cognitive decline in multiple domains affecting daily function, distinct from mild cognitive impairment where function is preserved
• MoCA provides greater sensitivity than MMSE for mild cognitive impairment and executive dysfunction; scores below twenty-six suggest impairment
• Alzheimer's disease is the most common dementia, characterized by memory-predominant presentation, gradual progression, and hippocampal atrophy on MRI
• Biomarkers (CSF amyloid/tau, amyloid PET) now biologically define Alzheimer's disease and guide emerging disease-modifying therapies
• Vascular dementia features executive dysfunction predominance, stepwise or gradual course, and white matter hyperintensities on MRI
• Behavioral variant FTD presents with early personality change, disinhibition, apathy, and compulsive behaviors, typically before age sixty-five
• Lewy body dementia features fluctuating cognition, visual hallucinations, parkinsonism, and REM sleep behavior disorder
• Antipsychotics in Lewy body dementia carry risk of severe sensitivity reactions and increased mortality; avoid or use with extreme caution
• Normal pressure hydrocephalus presents with gait disturbance, dementia, and incontinence; ventriculoperitoneal shunt may improve symptoms
• Cholinesterase inhibitors provide modest symptomatic benefit; anti-amyloid therapies offer potential disease modification in early Alzheimer's disease

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown